Rocket Pharma Files 8-K on Financial Condition and Operations
Ticker: RCKTW · Form: 8-K · Filed: Feb 26, 2024 · CIK: 1281895
| Field | Detail |
|---|---|
| Company | Rocket Pharmaceuticals, Inc. (RCKTW) |
| Form Type | 8-K |
| Filed Date | Feb 26, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, operations, 8-K
TL;DR
**Rocket Pharmaceuticals just dropped an 8-K on their financials, so keep an eye out for details on their performance.**
AI Summary
Rocket Pharmaceuticals, Inc. filed an 8-K on February 26, 2024, reporting on its results of operations and financial condition. The filing, under SEC File Number 001-36829, indicates a current report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934. The company, based in New York, NY, with a business phone of (646) 440-9100, also included financial statements and exhibits.
Why It Matters
This filing provides an update on Rocket Pharmaceuticals' financial health and operational performance, which is crucial for investors to assess the company's stability and future prospects in the pharmaceutical industry.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial condition and operations, not indicating any immediate high-risk events.
Key Players & Entities
- Rocket Pharmaceuticals, Inc. (company) — registrant
- February 26, 2024 (date) — date of report
- 001-36829 (other) — Commission File Number
- New York, NY (other) — business address city and state
- (646) 440-9100 (other) — business phone number
FAQ
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported was February 26, 2024.
What is the Commission File Number for Rocket Pharmaceuticals, Inc.?
The Commission File Number for Rocket Pharmaceuticals, Inc. is 001-36829.
Where is Rocket Pharmaceuticals, Inc.'s principal executive office located?
Rocket Pharmaceuticals, Inc.'s principal executive office is located at 9 Cedarbrook Drive, Cranbury, NJ 08512.
What items were reported in this 8-K filing?
The 8-K filing reported on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.
What is the business phone number for Rocket Pharmaceuticals, Inc.?
The business phone number for Rocket Pharmaceuticals, Inc. is (646) 440-9100.
Filing Stats: 517 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-02-26 16:37:50
Key Financial Figures
- $0.01 — nge on which registered Common stock, $0.01 par value RCKT The Nasdaq Global Ma
Filing Documents
- ef20022436_8k.htm (8-K) — 29KB
- ef20022436_ex99-1.htm (EX-99.1) — 100KB
- image00003.jpg (GRAPHIC) — 4KB
- 0001140361-24-009506.txt ( ) — 278KB
- rckt-20240226.xsd (EX-101.SCH) — 4KB
- rckt-20240226_lab.xml (EX-101.LAB) — 21KB
- rckt-20240226_pre.xml (EX-101.PRE) — 16KB
- ef20022436_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition. On February 26, 2024, Rocket Pharmaceuticals, Inc. (the "Company") announced certain financial results for the quarter and full year ended December 31, 2023. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release of Rocket Pharmaceuticals, Inc. dated February 26, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Rocket Pharmaceuticals, Inc. Date: February 26, 2024 By: /s/ Martin Wilson Martin Wilson General Counsel and Chief Compliance Officer, SVP